Compare Vanguard Growth Index Fund ETF (VUG) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Growth Index Fund ETF vs 22nd Century Group Inc — how do they compare? Vanguard Growth Index Fund ETF trades at $87.92, while 22nd Century Group Inc trades at $2.12 (market cap $1.62M). The key difference: Vanguard Growth Index Fund ETF is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals.
| VUG | XXII | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $90.29 | $594.00 |
52-Week Low | $70.00 | $2.13 |
Market Cap | — | $1.62M |
Enterprise Value | — | -$2.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VUG trades at $88.12, down 0.37% on the day, with a bullish technical signal from moving averages but neutral oscillators. Recent news highlights institutional accumulation, with multiple advisors increasing stakes in Q2 2026. The fund's growth focus contrasts with value counterparts underperforming this year, as noted by financial media.
The outlook remains positive given strong institutional interest and low-fee structure, though risks include market volatility and sector concentration. Growth ETFs face competition, but VUG's large-cap exposure offers stability amid bullish market forecasts.
XXII trades at $2.29, down 4.58% today, showing continued bearish momentum with negative technical signals. The company faces severe financial challenges with negative profit margins (-76.01% net income margin) and consecutive earnings misses. Despite analyst optimism (75% buy ratings), fundamental weakness persists with declining revenue and substantial losses. Recent corporate actions include a 20:1 reverse stock split completed June 2026 to maintain listing compliance.
The outlook remains challenging given persistent operational losses and negative cash flow from operations. Investment opportunity exists if the company can capitalize on its claimed $50B market opportunity and improve gross margins. Key risks include continued cash burn, competitive pressures in tobacco alternatives, and execution challenges in commercializing VLN products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
